Literature DB >> 18826390

Some hemostasis variables at the end of the population distributions are risk factors for severe postpartum hemorrhages.

C Chauleur1, E Cochery-Nouvellon, E Mercier, G Aya, P Fabbro-Peray, P Mismetti, G Lissade-Lavigne, J-C Gris.   

Abstract

BACKGROUND: Severe postpartum hemorrhages (PPH) represent a significant cause of maternal morbidity/mortality, but little is known about its hemostasis-related risk factors. Among the 32 463 women enrolled in the NOHA First cohort, 317 developed severe PPH (S-PPH group), 1269 non-severe PPH (NS-PPH group) and the remaining individuals were considered as control women (C group).
METHODS: We performed a case-control study, including 317 triplets of women allocated from the three groups that shared the same clinical characteristics as the S-PPH group.
RESULTS: From values obtained 6-9 months after delivery, low (but not-deficient) levels of fibrinogen, von Willebrand factor (VWF) antigen, factor (F) XI, platelet CD42b, TRAP-induced increase of platelet CD41a and high values of serum residual prothrombin activity or closure aperture times using the collagen-ADP cartridge on the PFA-100 system, and blood group O, were independently associated with a significant risk of severe PPH. Being positive for at least two of these eight variables was found in 1.6%, 3.5% and 20.8% of the women from the C, the NS-PPH and the S-PPH groups, respectively, the odds ratio for S-PPH in such a case being 16.4, 95%CI (6.5-41), P < 0.0001.
CONCLUSIONS: Women with some hemostasis-related variables at the low or high end of the population distributions are prone to the severe forms of PPH. Clinical trials will allow us to know if acting on these risk factors can lower the clinical severity of PPH.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18826390     DOI: 10.1111/j.1538-7836.2008.03168.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  8 in total

Review 1.  Relationship between ABO blood group and pregnancy complications: a systematic literature analysis.

Authors:  Massimo Franchini; Carlo Mengoli; Giuseppe Lippi
Journal:  Blood Transfus       Date:  2016-05-05       Impact factor: 3.443

Review 2.  Platelet function tests: a comparative review.

Authors:  Rita Paniccia; Raffaella Priora; Agatina Alessandrello Liotta; Rosanna Abbate
Journal:  Vasc Health Risk Manag       Date:  2015-02-18

Review 3.  Platelet Aggregometry Testing: Molecular Mechanisms, Techniques and Clinical Implications.

Authors:  Katalin Koltai; Gabor Kesmarky; Gergely Feher; Antal Tibold; Kalman Toth
Journal:  Int J Mol Sci       Date:  2017-08-18       Impact factor: 5.923

4.  Association of ABO blood group with bleeding severity in patients with bleeding of unknown cause.

Authors:  Dino Mehic; Stefanie Hofer; Christof Jungbauer; Alexandra Kaider; Helmuth Haslacher; Ernst Eigenbauer; Judit Rejtő; Dieter Schwartz; Bernd Jilma; Cihan Ay; Ingrid Pabinger; Johanna Gebhart
Journal:  Blood Adv       Date:  2020-10-27

5.  The impact of blood type O on mortality of severe trauma patients: a retrospective observational study.

Authors:  Wataru Takayama; Akira Endo; Hazuki Koguchi; Momoko Sugimoto; Kiyoshi Murata; Yasuhiro Otomo
Journal:  Crit Care       Date:  2018-05-02       Impact factor: 9.097

6.  The influence of ABO blood group on mortality in major trauma.

Authors:  Uwe Hamsen; André Nohl; Andreas Baumann; Rolf Lefering; Laila Boutakmant; Christian Waydhas; Marcel Dudda; Thomas Armin Schildhauer; Marcus Jäger; Alexander Wegner
Journal:  Orthop Rev (Pavia)       Date:  2019-12-02

7.  [How I use fibrinogen replacement treatment in acquired bleeding].

Authors:  H Mei; Y Hu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2018-10-14

8.  Association of ABO Blood Type with Bleeding Severity in Patients with Acute Gastroesophageal Variceal Bleeding.

Authors:  Wei-Yu Lin; Ming-Yuan Hong; Chih-Hao Lin; Peng-Peng Chang; Shao-Chung Chu; Chia-Lung Kao
Journal:  Medicina (Kaunas)       Date:  2021-12-03       Impact factor: 2.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.